Immuneering : Statement of Changes in Beneficial Ownership (Form 4)

by


Ownership Submission

FORM 4

Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response…0.5

1. Name and Address of Reporting Person *

CARPENTER ROBERT J

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [IMRX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director

_____ 10% Owner

_____ Officer (give title below)

____ Other (specify below)

(Last)

(First)

(Middle)

245 MAIN STREET , SECOND FLOOR

3. Date of Earliest Transaction (Month/Day/Year)

(Street)

CAMBRIDGE

MA

02142

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Join/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code

4. Securities Acquired (A) or Disposed of (D)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s)

6. Ownership Form: Direct (D) or Indirect (I)

7. Nature of Indirect Beneficial Ownership

Code

V

Amount

(A) or (D)

Price

Table II – Derivative Securities Beneficially Owned (egputs, calls, warrants, options, convertible securities)
(egputs, calls, warrants, options, convertible securities)

1. Title of Derivate Security

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code

5. Number of Derivative Securities Acquired (A) or Disposed of (D)

6. Date Exercisable and Expiration Date

7. Title and Amount of Securities Underlying Derivative Security

8. Price of Derivative Security

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)

11. Nature of Indirect Beneficial Ownership

Code

V

(A)

(D)

Date Exercisable

Expriation Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships

Director

10% Owner

Officer

Other

CARPENTER ROBERT J
245 MAIN STREET
SECOND FLOOR
CAMBRIDGE, MA02142

Signatures

/s/ Michael D. Bookman, Attorney-in-Fact for Robert J. Carpenter

2022-06-23

**Signature of Reporting Person

Date

Explanation of Responses:

If the form is filed by more than one reporting person, see

Instruction 5(b)(v).

(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See

18 USC 1001 and 15 USC 78ff(a).

(1)

The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first . Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See

Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer Immuneering Corporation published this content on 23 June 2022 and is responsible for the information contained therein. Distributed by Public, unedited and unaltered, on23 June 2022 21:05:06 UTC

.

Publicnow 2022

All news about IMMUNEERING CORPORATION

Analyst Recommendations on IMMUNEERING CORPORATION

Sales 2022
0.66 M
–
– Net income 2022
-57,6 M
–
– Net cash 2022
88.8 M
–
– P/E ratio 2022
-2,21x Yield 2022
– Capitalization
125 M
125 M
– EV / Sales 2022
55,4x EV / Sales 2023
328x Nbr of Employees
68 Free-Float

69.4%
Chart IMMUNEERING CORPORATION

Immuneering Corporation Technical Analysis Chart | MarketScreener

Immuneering Corporation Technical Analysis Chart | MarketScreener

Technical analysis trends IMMUNEERING CORPORATION

Short Term Mid-Term
Long Term Trends Neutral Bearish

Bearish

Please enable JavaScript in your browser’s settings to use dynamic charts.

Sell
Buy Mean consensus
BUY Number of Analysts
6 Last Close Price
4.75 $ average target price
26,00 $ Spread / Average Target

Please enable JavaScript in your browser’s settings to use dynamic charts.

Leave a Comment